{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "26",
                "@timestamp": "2022-11-26T14:49:33.000033-05:00",
                "@year": "2022",
                "@month": "11"
            },
            "ait:date-sort": {
                "@day": "01",
                "@year": "2022",
                "@month": "01"
            }
        },
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60002620",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Faculty of Medicine"},
                                {"$": "Chulalongkorn University"}
                            ],
                            "affiliation-id": [
                                {"@afid": "60002620"},
                                {"@afid": "60028190"}
                            ],
                            "ce:source-text": "Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"
                        },
                        "author": [
                            {
                                "ce:given-name": "Pim",
                                "preferred-name": {
                                    "ce:given-name": "Pim",
                                    "ce:initials": "P.",
                                    "ce:surname": "Sermsaksasithorn",
                                    "ce:indexed-name": "Sermsaksasithorn P."
                                },
                                "@seq": "1",
                                "ce:initials": "P.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Sermsaksasithorn",
                                "@auid": "57763746000",
                                "ce:indexed-name": "Sermsaksasithorn P."
                            },
                            {
                                "ce:given-name": "Varin",
                                "preferred-name": {
                                    "ce:given-name": "Varin",
                                    "ce:initials": "V.",
                                    "ce:surname": "Chaaim",
                                    "ce:indexed-name": "Chaaim V."
                                },
                                "@seq": "3",
                                "ce:initials": "V.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Chaaim",
                                "@auid": "57764420400",
                                "ce:indexed-name": "Chaaim V."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60002620",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Faculty of Medicine"},
                                {"$": "Division of Dermatology"},
                                {"$": "Department of Medicine"},
                                {"$": "Chulalongkorn University"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60002620",
                                    "@dptid": "126231803"
                                },
                                {"@afid": "60028190"}
                            ],
                            "ce:source-text": "Faculty of Medicine, Division of Dermatology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand",
                            "@dptid": "126231803"
                        },
                        "author": [
                            {
                                "ce:given-name": "Chanidapa",
                                "preferred-name": {
                                    "ce:given-name": "Chanidapa",
                                    "ce:initials": "C.",
                                    "ce:surname": "Wongtada",
                                    "ce:indexed-name": "Wongtada C."
                                },
                                "@seq": "2",
                                "ce:initials": "C.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Wongtada",
                                "@auid": "57226428403",
                                "ce:indexed-name": "Wongtada C."
                            },
                            {
                                "ce:given-name": "Pravit",
                                "preferred-name": {
                                    "ce:given-name": "Pravit",
                                    "ce:initials": "P.",
                                    "ce:surname": "Asawanonda",
                                    "ce:indexed-name": "Asawanonda P."
                                },
                                "@seq": "5",
                                "ce:initials": "P.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Asawanonda",
                                "@auid": "6603000286",
                                "@orcid": "0000-0001-6764-9144",
                                "ce:indexed-name": "Asawanonda P."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60002620",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Faculty of Medicine"},
                                {"$": "Biostatistics Excellence Center"},
                                {"$": "Research Affairs"},
                                {"$": "Chulalongkorn University"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60002620",
                                    "@dptid": "128055199"
                                },
                                {"@afid": "60028190"}
                            ],
                            "ce:source-text": "Faculty of Medicine, Biostatistics Excellence Center, Research Affairs, Chulalongkorn University, Bangkok, Thailand",
                            "@dptid": "128055199"
                        },
                        "author": [{
                            "ce:given-name": "Yuda",
                            "preferred-name": {
                                "ce:given-name": "Yuda",
                                "ce:initials": "Y.",
                                "ce:surname": "Chongpison",
                                "ce:indexed-name": "Chongpison Y."
                            },
                            "@seq": "4",
                            "ce:initials": "Y.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Chongpison",
                            "@auid": "6504499118",
                            "ce:indexed-name": "Chongpison Y."
                        }]
                    }
                ],
                "citation-title": "On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study",
                "abstracts": "Â© 2022 Taylor & Francis Group, LLC.Background: Off-label uses of biologics in the treatment of psoriasis are usually implemented in limited-resource settings and studies regarding their response profiles are limited. Method: This was a retrospective study performed in moderate-to-severe plaque-type psoriasis patients who had been treated with either secukinumab, ixekizumab or brodalumab at a university hospital in Thailand between 1 January 2017 and 1 April 2021. Results: A total of 142 patients were included in the data analysis consisting of three groups of 48 patients, 86 patients, and 8 patients treated by secukinumab, ixekizumab, and brodalumab, respectively. Patients were then classified into five groups according to the dosing pattern they received; on-label, off-label with induction, off-label with specific pattern, off-label with irregular dosing interval <8 weeks and >8 weeks. Considering both secukinumab and ixekizumab, the adjusted hazard ratios (95%CI) for complete skin clearance of the four off-label regimens were 2.2(0.9\u20135.2), 1.9 (0.9\u20133.9), 1.0 (0.4\u20132.2), and 1.6 (0.7\u20133.6), compared to on-label regimen, respectively. In each biologic drug, almost all off-label dosing regimens demonstrated higher adjusted hazard ratios compared to on-label regimen. Conclusion: Off-label, patient-oriented regimens could be a promising choice of IL-17 inhibitors for administration in special settings. Off-label regimens are not inferior in terms of skin clearance to an on-label regimen in the efficacy of psoriasis treatment of secukinumab and ixekizumab but do cause more flares. The decision to use off-label regimens must account for the benefits and associated risks.",
                "correspondence": {
                    "affiliation": {
                        "country": "Thailand",
                        "address-part": "1873 Rama IV Road, Pathumwan",
                        "postal-code": "10330",
                        "@country": "tha",
                        "city": "Bangkok",
                        "organization": [
                            {"$": "Faculty of Medicine"},
                            {"$": "Division of Dermatology"},
                            {"$": "Department of Medicine"},
                            {"$": "Chulalongkorn University"}
                        ],
                        "ce:source-text": "Faculty of Medicine, Division of Dermatology, Department of Medicine, Chulalongkorn University, 1873 Rama IV Road, Pathumwan, Bangkok, 10330, Thailand"
                    },
                    "person": {
                        "ce:given-name": "Pravit",
                        "ce:initials": "P.",
                        "ce:surname": "Asawanonda",
                        "ce:indexed-name": "Asawanonda P."
                    }
                },
                "citation-info": {
                    "author-keywords": {"author-keyword": [
                        {
                            "$": "biologics",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "brodalumab",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "interleukin-17 inhibitors",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "ixekizumab",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "Psoriasis",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "secukinumab",
                            "@xml:lang": "eng",
                            "@original": "y"
                        }
                    ]},
                    "citation-type": {"@code": "ar"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "website": {"ce:e-address": {
                        "$": "http://www.tandfonline.com/loi/ijdt20",
                        "@type": "email"
                    }},
                    "translated-sourcetitle": {
                        "$": "Journal of Dermatological Treatment",
                        "@xml:lang": "eng"
                    },
                    "volisspag": {
                        "voliss": {
                            "@volume": "33",
                            "@issue": "7"
                        },
                        "pagerange": {
                            "@first": "2963",
                            "@last": "2974"
                        }
                    },
                    "@type": "j",
                    "sourcetitle": "Journal of Dermatological Treatment",
                    "publicationdate": {
                        "year": "2022",
                        "date-text": {
                            "@xfab-added": "true",
                            "$": "2022"
                        }
                    },
                    "codencode": "JDTRE",
                    "sourcetitle-abbrev": "J. Dermatol. Treat.",
                    "@country": "gbr",
                    "issn": [
                        {
                            "$": "14711753",
                            "@type": "electronic"
                        },
                        {
                            "$": "09546634",
                            "@type": "print"
                        }
                    ],
                    "publicationyear": {"@first": "2022"},
                    "publisher": {"publishername": "Taylor and Francis Ltd."},
                    "@srcid": "24862"
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "EMCLASS",
                            "classification": [
                                {
                                    "classification-code": "13",
                                    "classification-description": "Dermatology and Venereology"
                                },
                                {
                                    "classification-code": "37",
                                    "classification-description": "Drug Literature Index"
                                }
                            ]
                        },
                        {
                            "@type": "ASJC",
                            "classification": "2708"
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": "MEDI"
                        }
                    ]},
                    "chemicalgroup": {"chemicals": [
                        {
                            "@source": "esbd",
                            "chemical": [
                                {
                                    "cas-registry-number": "446-86-6",
                                    "chemical-name": "azathioprine"
                                },
                                {
                                    "cas-registry-number": "1174395-19-7",
                                    "chemical-name": "brodalumab"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "59865-13-3"},
                                        {"$": "63798-73-2"},
                                        {"$": "79217-60-0"}
                                    ],
                                    "chemical-name": "cyclosporine"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "185243-69-0"},
                                        {"$": "200013-86-1"},
                                        {"$": "2055118-96-0"}
                                    ],
                                    "chemical-name": "etanercept"
                                },
                                {
                                    "cas-registry-number": "55079-83-9",
                                    "chemical-name": "etretin"
                                },
                                {
                                    "cas-registry-number": "1350289-85-8",
                                    "chemical-name": "guselkumab"
                                },
                                {
                                    "cas-registry-number": "1143503-69-8",
                                    "chemical-name": "ixekizumab"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "15475-56-6"},
                                        {"$": "59-05-2"},
                                        {"$": "7413-34-5"},
                                        {"$": "7532-09-4"},
                                        {"$": "6745-93-3"},
                                        {"$": "51865-79-3"},
                                        {"$": "60388-53-6"}
                                    ],
                                    "chemical-name": "methotrexate"
                                },
                                {
                                    "cas-registry-number": "599-79-1",
                                    "chemical-name": "salazosulfapyridine"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "875356-43-7"},
                                        {"$": "875356-44-8"},
                                        {"$": "1229022-83-6"}
                                    ],
                                    "chemical-name": "secukinumab"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "815610-63-0"},
                                        {"$": "949907-93-1"}
                                    ],
                                    "chemical-name": "ustekinumab"
                                }
                            ]
                        },
                        {
                            "@source": "nlm",
                            "chemical": [
                                {"chemical-name": "Antibodies, Monoclonal"},
                                {"chemical-name": "Biological Products"},
                                {"chemical-name": "Interleukin Inhibitors"},
                                {"chemical-name": "Interleukin-17"}
                            ]
                        }
                    ]}
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2022 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "external-source": "MEDLINE",
                "dbcollection": [
                    {"$": "EMBASE"},
                    {"$": "MEDL"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "25",
                    "@timestamp": "BST 14:25:51",
                    "@year": "2022",
                    "@month": "11"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2018002274",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "638231695",
                            "@idtype": "associatedPUI"
                        },
                        {
                            "$": "941132212",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20220580638",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "35695280",
                            "@idtype": "MEDL"
                        },
                        {
                            "$": "20221959239",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20222205790",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "20229013462148",
                            "@idtype": "TPA-ID"
                        },
                        {
                            "$": "85132820752",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85132820752",
                            "@idtype": "SGR"
                        },
                        {
                            "$": "638231695",
                            "@idtype": "PUIsecondary"
                        },
                        {
                            "$": "76746699",
                            "@idtype": "OSIN"
                        }
                    ],
                    "ce:doi": "10.1080/09546634.2022.2089328"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "74",
                "reference": [
                    {
                        "ref-fulltext": "Golden JB, McCormick TS, Ward NL. IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine. 2013; 62 (2): 195\u2013201.",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0001",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84876816203",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "62",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "195",
                                    "@last": "201"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.B.",
                                    "@_fa": "true",
                                    "ce:surname": "Golden",
                                    "ce:indexed-name": "Golden J.B."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "T.S.",
                                    "@_fa": "true",
                                    "ce:surname": "McCormick",
                                    "ce:indexed-name": "McCormick T.S."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "N.L.",
                                    "@_fa": "true",
                                    "ce:surname": "Ward",
                                    "ce:indexed-name": "Ward N.L."
                                }
                            ]},
                            "ref-sourcetitle": "Cytokine"
                        },
                        "ce:source-text": "Golden JB, McCormick TS, Ward NL. IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine. 2013; 62 (2): 195\u2013201."
                    },
                    {
                        "ref-fulltext": "Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018; 55 (3): 379\u2013390.",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0002",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85051703989",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "55",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "379",
                                    "@last": "390"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Blauvelt",
                                    "ce:indexed-name": "Blauvelt A."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Chiricozzi",
                                    "ce:indexed-name": "Chiricozzi A."
                                }
                            ]},
                            "ref-sourcetitle": "Clin Rev Allergy Immunol"
                        },
                        "ce:source-text": "Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018; 55 (3): 379\u2013390."
                    },
                    {
                        "ref-fulltext": "Hanley TL, Yiu ZZ. Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab. Ther Clin Risk Manag. 2017; 13: 315\u2013323.",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0003",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85015278599",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "13"},
                                "pagerange": {
                                    "@first": "315",
                                    "@last": "323"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "T.L.",
                                    "@_fa": "true",
                                    "ce:surname": "Hanley",
                                    "ce:indexed-name": "Hanley T.L."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "Z.Z.",
                                    "@_fa": "true",
                                    "ce:surname": "Yiu",
                                    "ce:indexed-name": "Yiu Z.Z."
                                }
                            ]},
                            "ref-sourcetitle": "Ther Clin Risk Manag"
                        },
                        "ce:source-text": "Hanley TL, Yiu ZZ. Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab. Ther Clin Risk Manag. 2017; 13: 315\u2013323."
                    },
                    {
                        "ref-fulltext": "Ten Bergen LL, Petrovic A, Krogh Aarebrot A, et al. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol. 2020; 92 (4): e12946.",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0004",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85091884329",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "92",
                                    "@issue": "4"
                                },
                                "pagerange": {"@first": "e12946"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Ten Bergen",
                                        "ce:indexed-name": "Ten Bergen L.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Petrovic",
                                        "ce:indexed-name": "Petrovic A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Krogh Aarebrot",
                                        "ce:indexed-name": "Krogh Aarebrot A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Scand J Immunol"
                        },
                        "ce:source-text": "Ten Bergen LL, Petrovic A, Krogh Aarebrot A, et al. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol. 2020; 92 (4): e12946."
                    },
                    {
                        "ref-fulltext": "Chiricozzi A, Balato A, Conrad C, et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J Dermatolog Treat. 2020; 31 (5): 476\u2013483.",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0005",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85074042506",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "31",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "476",
                                    "@last": "483"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Chiricozzi",
                                        "ce:indexed-name": "Chiricozzi A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Balato",
                                        "ce:indexed-name": "Balato A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Conrad",
                                        "ce:indexed-name": "Conrad C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Dermatolog Treat"
                        },
                        "ce:source-text": "Chiricozzi A, Balato A, Conrad C, et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J Dermatolog Treat. 2020; 31 (5): 476\u2013483."
                    },
                    {
                        "ref-fulltext": "Bai F, Li GG, Liu Q, et al. Short-Term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network Meta-Analysis of randomized controlled trials. J Immunol Res. 2019; 2019: 2546161.",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Short-Term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network Meta-Analysis of randomized controlled trials"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0006",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85072739574",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "2019"},
                                "pagerange": {"@first": "2546161"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Bai",
                                        "ce:indexed-name": "Bai F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.G.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li G.G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Q.",
                                        "@_fa": "true",
                                        "ce:surname": "Liu",
                                        "ce:indexed-name": "Liu Q."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Immunol Res"
                        },
                        "ce:source-text": "Bai F, Li GG, Liu Q, et al. Short-Term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network Meta-Analysis of randomized controlled trials. J Immunol Res. 2019; 2019: 2546161."
                    },
                    {
                        "ref-fulltext": "Bilal J, Berlinberg A, Bhattacharjee S, et al. A systematic review and Meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat. 2018; 29 (6): 569\u2013578.",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "A systematic review and Meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0007",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85044475552",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "29",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "569",
                                    "@last": "578"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Bilal",
                                        "ce:indexed-name": "Bilal J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Berlinberg",
                                        "ce:indexed-name": "Berlinberg A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Bhattacharjee",
                                        "ce:indexed-name": "Bhattacharjee S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Dermatolog Treat"
                        },
                        "ce:source-text": "Bilal J, Berlinberg A, Bhattacharjee S, et al. A systematic review and Meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat. 2018; 29 (6): 569\u2013578."
                    },
                    {
                        "ref-fulltext": "Facheris P, Valenti M, Pavia G, et al. Brodalumab: a new way to inhibit IL-17 in psoriasis. Dermatol Ther. 2020; 33 (3): e13403.",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Brodalumab: a new way to inhibit IL-17 in psoriasis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0008",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85084138095",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "33",
                                    "@issue": "3"
                                },
                                "pagerange": {"@first": "e13403"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Facheris",
                                        "ce:indexed-name": "Facheris P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Valenti",
                                        "ce:indexed-name": "Valenti M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Pavia",
                                        "ce:indexed-name": "Pavia G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Dermatol Ther"
                        },
                        "ce:source-text": "Facheris P, Valenti M, Pavia G, et al. Brodalumab: a new way to inhibit IL-17 in psoriasis. Dermatol Ther. 2020; 33 (3): e13403."
                    },
                    {
                        "ref-fulltext": "Fargnoli MC. Secukinumab: the anti-IL-17A biologic for the treatment of psoriasis. Case Rep Dermatol. 2019; 11 (Suppl 1): 1\u20133.",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Secukinumab: the anti-IL-17A biologic for the treatment of psoriasis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0009",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85072800711",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "11"},
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "3"
                                }
                            },
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "M.C.",
                                "@_fa": "true",
                                "ce:surname": "Fargnoli",
                                "ce:indexed-name": "Fargnoli M.C."
                            }]},
                            "ref-sourcetitle": "Case Rep Dermatol"
                        },
                        "ce:source-text": "Fargnoli MC. Secukinumab: the anti-IL-17A biologic for the treatment of psoriasis. Case Rep Dermatol. 2019; 11 (Suppl 1): 1\u20133."
                    },
                    {
                        "ref-fulltext": "Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018; 9 (1): 5\u201321.",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0010",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85040332497",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "9",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "5",
                                    "@last": "21"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Frieder",
                                    "ce:indexed-name": "Frieder J."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "D.",
                                    "@_fa": "true",
                                    "ce:surname": "Kivelevitch",
                                    "ce:indexed-name": "Kivelevitch D."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Menter",
                                    "ce:indexed-name": "Menter A."
                                }
                            ]},
                            "ref-sourcetitle": "Ther Adv Chronic Dis"
                        },
                        "ce:source-text": "Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018; 9 (1): 5\u201321."
                    },
                    {
                        "ref-fulltext": "Georgakopoulos JR, Ighani A, Zhou LL, et al. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study. J Eur Acad Dermatol Venereol. 2018; 32 (1): e32\u2013e34.",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0011",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85026641852",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "32",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "e32",
                                    "@last": "e34"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Georgakopoulos",
                                        "ce:indexed-name": "Georgakopoulos J.R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Ighani",
                                        "ce:indexed-name": "Ighani A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhou",
                                        "ce:indexed-name": "Zhou L.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Eur Acad Dermatol Venereol"
                        },
                        "ce:source-text": "Georgakopoulos JR, Ighani A, Zhou LL, et al. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study. J Eur Acad Dermatol Venereol. 2018; 32 (1): e32\u2013e34."
                    },
                    {
                        "ref-fulltext": "Georgakopoulos JR, Lam K, Sandhu VK, et al. Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study. J Eur Acad Dermatol Venereol. 2020; 34 (8): e416\u2013e418.",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0012",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85084354032",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "34",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "e416",
                                    "@last": "e418"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Georgakopoulos",
                                        "ce:indexed-name": "Georgakopoulos J.R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Lam",
                                        "ce:indexed-name": "Lam K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "V.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Sandhu",
                                        "ce:indexed-name": "Sandhu V.K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Eur Acad Dermatol Venereol"
                        },
                        "ce:source-text": "Georgakopoulos JR, Lam K, Sandhu VK, et al. Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study. J Eur Acad Dermatol Venereol. 2020; 34 (8): e416\u2013e418."
                    },
                    {
                        "ref-fulltext": "Puig L. Brodalumab: the first anti-IL-17 receptor agent for psoriasis. Drugs Today (Barc). 2017; 53 (5): 283\u2013297.",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Brodalumab: the first anti-IL-17 receptor agent for psoriasis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0013",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85020637890",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "53",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "283",
                                    "@last": "297"
                                }
                            },
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "L.",
                                "@_fa": "true",
                                "ce:surname": "Puig",
                                "ce:indexed-name": "Puig L."
                            }]},
                            "ref-sourcetitle": "Drugs Today (Barc)"
                        },
                        "ce:source-text": "Puig L. Brodalumab: the first anti-IL-17 receptor agent for psoriasis. Drugs Today (Barc). 2017; 53 (5): 283\u2013297."
                    },
                    {
                        "ref-fulltext": "Ratner M. IL-17-targeting biologics aim to become standard of care in psoriasis. Nat Biotechnol. 2015; 33 (1): 3\u20134.",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "IL-17-targeting biologics aim to become standard of care in psoriasis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0014",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84942097859",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "33",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "3",
                                    "@last": "4"
                                }
                            },
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "M.",
                                "@_fa": "true",
                                "ce:surname": "Ratner",
                                "ce:indexed-name": "Ratner M."
                            }]},
                            "ref-sourcetitle": "Nat Biotechnol"
                        },
                        "ce:source-text": "Ratner M. IL-17-targeting biologics aim to become standard of care in psoriasis. Nat Biotechnol. 2015; 33 (1): 3\u20134."
                    },
                    {
                        "ref-fulltext": "Tong Y, Peranteau AJ, Nawas Z, et al. A review of brodalumab, an IL-17 receptor antagonist, for moderate-to-Severe plaque psoriasis. Skin Therapy Lett. 2017; 22 (1): 1\u20136.",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "A review of brodalumab, an IL-17 receptor antagonist, for moderate-to-Severe plaque psoriasis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0015",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85020634949",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "22",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "1",
                                    "@last": "6"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Tong",
                                        "ce:indexed-name": "Tong Y."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Peranteau",
                                        "ce:indexed-name": "Peranteau A.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Z.",
                                        "@_fa": "true",
                                        "ce:surname": "Nawas",
                                        "ce:indexed-name": "Nawas Z."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Skin Therapy Lett"
                        },
                        "ce:source-text": "Tong Y, Peranteau AJ, Nawas Z, et al. A review of brodalumab, an IL-17 receptor antagonist, for moderate-to-Severe plaque psoriasis. Skin Therapy Lett. 2017; 22 (1): 1\u20136."
                    },
                    {
                        "ref-fulltext": "van Vugt LJ, van den Reek JMPA, Meulewaeter E, et al. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020; 34 (1): 112\u2013118.",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0016",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85070441429",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "34",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "112",
                                    "@last": "118"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.J.",
                                        "@_fa": "true",
                                        "ce:surname": "van Vugt",
                                        "ce:indexed-name": "van Vugt L.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.M.P.A.",
                                        "@_fa": "true",
                                        "ce:surname": "van den Reek",
                                        "ce:indexed-name": "van den Reek J.M.P.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Meulewaeter",
                                        "ce:indexed-name": "Meulewaeter E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Eur Acad Dermatol Venereol"
                        },
                        "ce:source-text": "van Vugt LJ, van den Reek JMPA, Meulewaeter E, et al. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020; 34 (1): 112\u2013118."
                    },
                    {
                        "ref-fulltext": "Yamauchi PS, Bagel J. Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition. J Drugs Dermatol. 2015; 14 (3): 244\u2013253.",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0017",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84924656946",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "14",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "244",
                                    "@last": "253"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "P.S.",
                                    "@_fa": "true",
                                    "ce:surname": "Yamauchi",
                                    "ce:indexed-name": "Yamauchi P.S."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Bagel",
                                    "ce:indexed-name": "Bagel J."
                                }
                            ]},
                            "ref-sourcetitle": "J Drugs Dermatol"
                        },
                        "ce:source-text": "Yamauchi PS, Bagel J. Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition. J Drugs Dermatol. 2015; 14 (3): 244\u2013253."
                    },
                    {
                        "ref-fulltext": "Armstrong AW, Soliman AM, Betts KA, et al. Long-Term Benefit-Risk profiles of treatments for moderate-to-Severe plaque psoriasis: a network Meta-Analysis. Dermatol Ther (Heidelb). 2022; 12 (1): 167\u2013184.",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Long-Term Benefit-Risk profiles of treatments for moderate-to-Severe plaque psoriasis: a network Meta-Analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0018",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85120613714",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "12",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "167",
                                    "@last": "184"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Armstrong",
                                        "ce:indexed-name": "Armstrong A.W."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Soliman",
                                        "ce:indexed-name": "Soliman A.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Betts",
                                        "ce:indexed-name": "Betts K.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Dermatol Ther (Heidelb)"
                        },
                        "ce:source-text": "Armstrong AW, Soliman AM, Betts KA, et al. Long-Term Benefit-Risk profiles of treatments for moderate-to-Severe plaque psoriasis: a network Meta-Analysis. Dermatol Ther (Heidelb). 2022; 12 (1): 167\u2013184."
                    },
                    {
                        "ref-fulltext": "Perrone V, Losi S, Maiorino A, et al. Treatment patterns and pharmacoutilization in patients affected by psoriasis: an observational study in an Italian Real-World setting. Drugs Real World Outcomes. 2022; 9 (2): 243\u2013251.",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Treatment patterns and pharmacoutilization in patients affected by psoriasis: an observational study in an Italian Real-World setting"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0019",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85123182759",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "9",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "243",
                                    "@last": "251"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Perrone",
                                        "ce:indexed-name": "Perrone V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Losi",
                                        "ce:indexed-name": "Losi S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Maiorino",
                                        "ce:indexed-name": "Maiorino A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Drugs Real World Outcomes"
                        },
                        "ce:source-text": "Perrone V, Losi S, Maiorino A, et al. Treatment patterns and pharmacoutilization in patients affected by psoriasis: an observational study in an Italian Real-World setting. Drugs Real World Outcomes. 2022; 9 (2): 243\u2013251."
                    },
                    {
                        "ref-fulltext": "Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015; 73 (1): 27\u201336.e1.",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0020",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "e1",
                                    "@idtype": "ARTNUM"
                                },
                                {
                                    "$": "84937972700",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "73",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "27",
                                    "@last": "36"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "U.",
                                        "@_fa": "true",
                                        "ce:surname": "Mrowietz",
                                        "ce:indexed-name": "Mrowietz U."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Leonardi",
                                        "ce:indexed-name": "Leonardi C.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Girolomoni",
                                        "ce:indexed-name": "Girolomoni G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Am Acad Dermatol"
                        },
                        "ce:source-text": "Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015; 73 (1): 27\u201336.e1."
                    },
                    {
                        "ref-fulltext": "Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013; 168 (2): 402\u2013411.",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0021",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84873168729",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "168",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "402",
                                    "@last": "411"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Rich",
                                        "ce:indexed-name": "Rich P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Sigurgeirsson",
                                        "ce:indexed-name": "Sigurgeirsson B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Thaci",
                                        "ce:indexed-name": "Thaci D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Br J Dermatol"
                        },
                        "ce:source-text": "Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013; 168 (2): 402\u2013411."
                    },
                    {
                        "ref-fulltext": "Blauvelt A, Papp KA, Sofen H, et al. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J Eur Acad Dermatol Venereol. 2017; 31 (6): 1004\u20131013.",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0022",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85017400588",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "31",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "1004",
                                    "@last": "1013"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Blauvelt",
                                        "ce:indexed-name": "Blauvelt A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Papp",
                                        "ce:indexed-name": "Papp K.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Sofen",
                                        "ce:indexed-name": "Sofen H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Eur Acad Dermatol Venereol"
                        },
                        "ce:source-text": "Blauvelt A, Papp KA, Sofen H, et al. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J Eur Acad Dermatol Venereol. 2017; 31 (6): 1004\u20131013."
                    },
                    {
                        "ref-fulltext": "Michielsens CAJ, van Muijen ME, Verhoef LM, et al. Dose tapering of biologics in patients with psoriasis: a scoping review. Drugs. 2021; 81 (3): 349\u2013366.",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Dose tapering of biologics in patients with psoriasis: a scoping review"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0023",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85100134549",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "81",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "349",
                                    "@last": "366"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.A.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Michielsens",
                                        "ce:indexed-name": "Michielsens C.A.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.E.",
                                        "@_fa": "true",
                                        "ce:surname": "van Muijen",
                                        "ce:indexed-name": "van Muijen M.E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Verhoef",
                                        "ce:indexed-name": "Verhoef L.M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Drugs"
                        },
                        "ce:source-text": "Michielsens CAJ, van Muijen ME, Verhoef LM, et al. Dose tapering of biologics in patients with psoriasis: a scoping review. Drugs. 2021; 81 (3): 349\u2013366."
                    },
                    {
                        "ref-fulltext": "Al-Hammadi A, Ruszczak Z, MagariÃ±os G, et al. Intermittent use of biologic agents for the treatment of psoriasis in adults. J Eur Acad Dermatol Venereol. 2021; 35 (2): 360\u2013367.",
                        "@id": "24",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Intermittent use of biologic agents for the treatment of psoriasis in adults"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0024",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85089977463",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "35",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "360",
                                    "@last": "367"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Al-Hammadi",
                                        "ce:indexed-name": "Al-Hammadi A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Z.",
                                        "@_fa": "true",
                                        "ce:surname": "Ruszczak",
                                        "ce:indexed-name": "Ruszczak Z."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "MagariÃ±os",
                                        "ce:indexed-name": "Magarinos G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Eur Acad Dermatol Venereol"
                        },
                        "ce:source-text": "Al-Hammadi A, Ruszczak Z, MagariÃ±os G, et al. Intermittent use of biologic agents for the treatment of psoriasis in adults. J Eur Acad Dermatol Venereol. 2021; 35 (2): 360\u2013367."
                    },
                    {
                        "ref-fulltext": "Siegfried EC, Eichenfield LF, Paller AS, et al. Intermittent etanercept therapy in pediatric patients with psoriasis. J Am Acad Dermatol. 2010; 63 (5): 769\u2013774.",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2010"},
                            "ref-title": {"ref-titletext": "Intermittent etanercept therapy in pediatric patients with psoriasis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0025",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "77957978331",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "63",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "769",
                                    "@last": "774"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Siegfried",
                                        "ce:indexed-name": "Siegfried E.C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.F.",
                                        "@_fa": "true",
                                        "ce:surname": "Eichenfield",
                                        "ce:indexed-name": "Eichenfield L.F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Paller",
                                        "ce:indexed-name": "Paller A.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Am Acad Dermatol"
                        },
                        "ce:source-text": "Siegfried EC, Eichenfield LF, Paller AS, et al. Intermittent etanercept therapy in pediatric patients with psoriasis. J Am Acad Dermatol. 2010; 63 (5): 769\u2013774."
                    },
                    {
                        "ref-fulltext": "Schwensen JF, Clemmensen A, Sand C, et al. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: a retrospective multicenter study. Dermatol Ther. 2017; 30 (6).",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: a retrospective multicenter study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0026",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85037032305",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {
                                "@volume": "30",
                                "@issue": "6"
                            }},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.F.",
                                        "@_fa": "true",
                                        "ce:surname": "Schwensen",
                                        "ce:indexed-name": "Schwensen J.F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Clemmensen",
                                        "ce:indexed-name": "Clemmensen A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Sand",
                                        "ce:indexed-name": "Sand C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Dermatol Ther"
                        },
                        "ce:source-text": "Schwensen JF, Clemmensen A, Sand C, et al. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: a retrospective multicenter study. Dermatol Ther. 2017; 30 (6)."
                    },
                    {
                        "ref-fulltext": "Zhu SM, Wang WH, Guo JZ, et al. Effectiveness and safety of secukinumab in Chinese patients with plaque psoriasis in a clinical practice setting: a pilot study. Chin Med J (Engl). 2020; 133 (24): 3017\u20133019.",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Effectiveness and safety of secukinumab in Chinese patients with plaque psoriasis in a clinical practice setting: a pilot study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0027",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85098743599",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "133",
                                    "@issue": "24"
                                },
                                "pagerange": {
                                    "@first": "3017",
                                    "@last": "3019"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhu",
                                        "ce:indexed-name": "Zhu S.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "W.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang W.H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.Z.",
                                        "@_fa": "true",
                                        "ce:surname": "Guo",
                                        "ce:indexed-name": "Guo J.Z."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Chin Med J (Engl)"
                        },
                        "ce:source-text": "Zhu SM, Wang WH, Guo JZ, et al. Effectiveness and safety of secukinumab in Chinese patients with plaque psoriasis in a clinical practice setting: a pilot study. Chin Med J (Engl). 2020; 133 (24): 3017\u20133019."
                    },
                    {
                        "ref-fulltext": "Colombo D, Bianchi L, Fabbrocini G, et al. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study. Dermatol Ther. 2022; 35 (1): e15166.",
                        "@id": "28",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0028",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85119697642",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "35",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "e15166"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Colombo",
                                        "ce:indexed-name": "Colombo D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Bianchi",
                                        "ce:indexed-name": "Bianchi L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Fabbrocini",
                                        "ce:indexed-name": "Fabbrocini G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Dermatol Ther"
                        },
                        "ce:source-text": "Colombo D, Bianchi L, Fabbrocini G, et al. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study. Dermatol Ther. 2022; 35 (1): e15166."
                    },
                    {
                        "ref-fulltext": "Jabbar-Lopez ZK, Yiu ZZN, Ward V, et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network Meta-Analysis. J Invest Dermatol. 2017; 137 (8): 1646\u20131654.",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network Meta-Analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0029",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85024833789",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "137",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "1646",
                                    "@last": "1654"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Z.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Jabbar-Lopez",
                                        "ce:indexed-name": "Jabbar-Lopez Z.K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Z.Z.N.",
                                        "@_fa": "true",
                                        "ce:surname": "Yiu",
                                        "ce:indexed-name": "Yiu Z.Z.N."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Ward",
                                        "ce:indexed-name": "Ward V."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Invest Dermatol"
                        },
                        "ce:source-text": "Jabbar-Lopez ZK, Yiu ZZN, Ward V, et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network Meta-Analysis. J Invest Dermatol. 2017; 137 (8): 1646\u20131654."
                    },
                    {
                        "ref-fulltext": "Sawyer LM, Malottki K, Sabry-Grant C, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network Meta-analysis of PASI response. PLoS One. 2019; 14 (8): e0220868.",
                        "@id": "30",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network Meta-analysis of PASI response"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0030",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "e0220868",
                                    "@idtype": "ARTNUM"
                                },
                                {
                                    "$": "85070662198",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {
                                "@volume": "14",
                                "@issue": "8"
                            }},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Sawyer",
                                        "ce:indexed-name": "Sawyer L.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Malottki",
                                        "ce:indexed-name": "Malottki K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Sabry-Grant",
                                        "ce:indexed-name": "Sabry-Grant C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "PLoS One"
                        },
                        "ce:source-text": "Sawyer LM, Malottki K, Sabry-Grant C, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network Meta-analysis of PASI response. PLoS One. 2019; 14 (8): e0220868."
                    },
                    {
                        "ref-fulltext": "Warren RB, Gooderham M, Burge R, et al. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: results from a network meta-analysis. J Am Acad Dermatol. 2020; 82 (5): 1138\u20131149.",
                        "@id": "31",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: results from a network meta-analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0031",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85080114959",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "82",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "1138",
                                    "@last": "1149"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Warren",
                                        "ce:indexed-name": "Warren R.B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Gooderham",
                                        "ce:indexed-name": "Gooderham M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Burge",
                                        "ce:indexed-name": "Burge R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Am Acad Dermatol"
                        },
                        "ce:source-text": "Warren RB, Gooderham M, Burge R, et al. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: results from a network meta-analysis. J Am Acad Dermatol. 2020; 82 (5): 1138\u20131149."
                    },
                    {
                        "ref-fulltext": "Warren RB, See K, Burge R, et al. Rapid response of biologic treatments of moderate-to-Severe plaque psoriasis: a comprehensive investigation using Bayesian and frequentist network Meta-analyses. Dermatol Ther (Heidelb). 2020; 10 (1): 73\u201386.",
                        "@id": "32",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Rapid response of biologic treatments of moderate-to-Severe plaque psoriasis: a comprehensive investigation using Bayesian and frequentist network Meta-analyses"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0032",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85074821752",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "10",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "73",
                                    "@last": "86"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Warren",
                                        "ce:indexed-name": "Warren R.B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "See",
                                        "ce:indexed-name": "See K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Burge",
                                        "ce:indexed-name": "Burge R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Dermatol Ther (Heidelb)"
                        },
                        "ce:source-text": "Warren RB, See K, Burge R, et al. Rapid response of biologic treatments of moderate-to-Severe plaque psoriasis: a comprehensive investigation using Bayesian and frequentist network Meta-analyses. Dermatol Ther (Heidelb). 2020; 10 (1): 73\u201386."
                    },
                    {
                        "ref-fulltext": "Tada Y, Watanabe R, Noma H, et al. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network Meta-analysis. J Dermatol Sci. 2020; 99 (1): 53\u201361.",
                        "@id": "33",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network Meta-analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0033",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85086944580",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "99",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "53",
                                    "@last": "61"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Tada",
                                        "ce:indexed-name": "Tada Y."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Watanabe",
                                        "ce:indexed-name": "Watanabe R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Noma",
                                        "ce:indexed-name": "Noma H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Dermatol Sci"
                        },
                        "ce:source-text": "Tada Y, Watanabe R, Noma H, et al. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network Meta-analysis. J Dermatol Sci. 2020; 99 (1): 53\u201361."
                    },
                    {
                        "ref-fulltext": "Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network Meta-analysis. Cochrane Database Syst Rev. 2020; 1 (1): CD011535.",
                        "@id": "34",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Systemic pharmacological treatments for chronic plaque psoriasis: a network Meta-analysis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0034",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85038951556",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "1",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "CD011535"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Sbidian",
                                        "ce:indexed-name": "Sbidian E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Chaimani",
                                        "ce:indexed-name": "Chaimani A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Afach",
                                        "ce:indexed-name": "Afach S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cochrane Database Syst Rev"
                        },
                        "ce:source-text": "Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network Meta-analysis. Cochrane Database Syst Rev. 2020; 1 (1): CD011535."
                    },
                    {
                        "ref-fulltext": "Zagni E, Bianchi L, Fabbrocini G, et al. A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study. BMC Health Serv Res. 2021; 21 (1): 924.",
                        "@id": "35",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0035",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85114400018",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "21",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "924"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Zagni",
                                        "ce:indexed-name": "Zagni E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Bianchi",
                                        "ce:indexed-name": "Bianchi L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Fabbrocini",
                                        "ce:indexed-name": "Fabbrocini G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "BMC Health Serv Res"
                        },
                        "ce:source-text": "Zagni E, Bianchi L, Fabbrocini G, et al. A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study. BMC Health Serv Res. 2021; 21 (1): 924."
                    },
                    {
                        "ref-fulltext": "Herrera-Acosta E, Garriga-Martina GG, SuÃ¡rez-PÃ©rez JA, et al. Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice. Dermatol Ther. 2020; 33 (3): e13313.",
                        "@id": "36",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0036",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85082199683",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "33",
                                    "@issue": "3"
                                },
                                "pagerange": {"@first": "e13313"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Herrera-Acosta",
                                        "ce:indexed-name": "Herrera-Acosta E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.G.",
                                        "@_fa": "true",
                                        "ce:surname": "Garriga-Martina",
                                        "ce:indexed-name": "Garriga-Martina G.G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.A.",
                                        "@_fa": "true",
                                        "ce:surname": "SuÃ¡rez-PÃ©rez",
                                        "ce:indexed-name": "Suarez-Perez J.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Dermatol Ther"
                        },
                        "ce:source-text": "Herrera-Acosta E, Garriga-Martina GG, SuÃ¡rez-PÃ©rez JA, et al. Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice. Dermatol Ther. 2020; 33 (3): e13313."
                    },
                    {
                        "ref-fulltext": "Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021; 184 (6): 1047\u20131058.",
                        "@id": "37",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0037",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85093966402",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "184",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "1047",
                                    "@last": "1058"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Blauvelt",
                                        "ce:indexed-name": "Blauvelt A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Leonardi",
                                        "ce:indexed-name": "Leonardi C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Elewski",
                                        "ce:indexed-name": "Elewski B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Br J Dermatol"
                        },
                        "ce:source-text": "Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021; 184 (6): 1047\u20131058."
                    },
                    {
                        "ref-fulltext": "Augustin M, Gallo G, See K, et al. Early response is associated with stable Long-Term response in psoriasis patients receiving ixekizumab or ustekinumab. J Drugs Dermatol. 2022; 21 (2): 122\u2013126.",
                        "@id": "38",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Early response is associated with stable Long-Term response in psoriasis patients receiving ixekizumab or ustekinumab"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0038",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85124277341",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "21",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "122",
                                    "@last": "126"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Augustin",
                                        "ce:indexed-name": "Augustin M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Gallo",
                                        "ce:indexed-name": "Gallo G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "See",
                                        "ce:indexed-name": "See K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Drugs Dermatol"
                        },
                        "ce:source-text": "Augustin M, Gallo G, See K, et al. Early response is associated with stable Long-Term response in psoriasis patients receiving ixekizumab or ustekinumab. J Drugs Dermatol. 2022; 21 (2): 122\u2013126."
                    },
                    {
                        "ref-fulltext": "Schweikert B, Malmberg C, NÃºÃ±ez M, et al. Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain. BMJ Open. 2020; 10 (8): e032552.",
                        "@id": "39",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0039",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85089481847",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "10",
                                    "@issue": "8"
                                },
                                "pagerange": {"@first": "e032552"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Schweikert",
                                        "ce:indexed-name": "Schweikert B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Malmberg",
                                        "ce:indexed-name": "Malmberg C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "NÃºÃ±ez",
                                        "ce:indexed-name": "Nunez M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "BMJ Open"
                        },
                        "ce:source-text": "Schweikert B, Malmberg C, NÃºÃ±ez M, et al. Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain. BMJ Open. 2020; 10 (8): e032552."
                    },
                    {
                        "ref-fulltext": "Zhao Y, Cai L, Liu XY, et al. Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study. Chin Med J (Engl). 2021; 134 (11): 1324\u20131328.",
                        "@id": "40",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0040",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85107711661",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "134",
                                    "@issue": "11"
                                },
                                "pagerange": {
                                    "@first": "1324",
                                    "@last": "1328"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhao",
                                        "ce:indexed-name": "Zhao Y."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Cai",
                                        "ce:indexed-name": "Cai L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "X.Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Liu",
                                        "ce:indexed-name": "Liu X.Y."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Chin Med J (Engl)"
                        },
                        "ce:source-text": "Zhao Y, Cai L, Liu XY, et al. Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study. Chin Med J (Engl). 2021; 134 (11): 1324\u20131328."
                    },
                    {
                        "ref-fulltext": "Xiong HZ, Gu JY, He ZG, et al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015; 8 (3): 3156\u20133172.",
                        "@id": "41",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0041",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84929158936",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "8",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "3156",
                                    "@last": "3172"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.Z.",
                                        "@_fa": "true",
                                        "ce:surname": "Xiong",
                                        "ce:indexed-name": "Xiong H.Z."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Gu",
                                        "ce:indexed-name": "Gu J.Y."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Z.G.",
                                        "@_fa": "true",
                                        "ce:surname": "He",
                                        "ce:indexed-name": "He Z.G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Int J Clin Exp Med"
                        },
                        "ce:source-text": "Xiong HZ, Gu JY, He ZG, et al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015; 8 (3): 3156\u20133172."
                    },
                    {
                        "ref-fulltext": "Xu C, Teeple A, Wu B, et al. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population. J Dermatolog Treat. 2022; 1\u20138.",
                        "@id": "42",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0042",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85123396957",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"pagerange": {
                                "@first": "1",
                                "@last": "8"
                            }},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Xu",
                                        "ce:indexed-name": "Xu C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Teeple",
                                        "ce:indexed-name": "Teeple A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Wu",
                                        "ce:indexed-name": "Wu B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Dermatolog Treat"
                        },
                        "ce:source-text": "Xu C, Teeple A, Wu B, et al. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population. J Dermatolog Treat. 2022; 1\u20138."
                    },
                    {
                        "ref-fulltext": "Reich K, Puig L, Szepietowski JC, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020; 182 (2): 304\u2013315.",
                        "@id": "43",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0043",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85073920017",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "182",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "304",
                                    "@last": "315"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Reich",
                                        "ce:indexed-name": "Reich K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Puig",
                                        "ce:indexed-name": "Puig L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Szepietowski",
                                        "ce:indexed-name": "Szepietowski J.C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Br J Dermatol"
                        },
                        "ce:source-text": "Reich K, Puig L, Szepietowski JC, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020; 182 (2): 304\u2013315."
                    },
                    {
                        "ref-fulltext": "Reich K, KÃ¶rber A, Mrowietz U, et al. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study. Br J Dermatol. 2021; 184 (5): 849\u2013856.",
                        "@id": "44",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0044",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85093515250",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "184",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "849",
                                    "@last": "856"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Reich",
                                        "ce:indexed-name": "Reich K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "KÃ¶rber",
                                        "ce:indexed-name": "Korber A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "U.",
                                        "@_fa": "true",
                                        "ce:surname": "Mrowietz",
                                        "ce:indexed-name": "Mrowietz U."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Br J Dermatol"
                        },
                        "ce:source-text": "Reich K, KÃ¶rber A, Mrowietz U, et al. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study. Br J Dermatol. 2021; 184 (5): 849\u2013856."
                    },
                    {
                        "ref-fulltext": "Enos CW, Ramos VL, McLean RR, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry. J Am Acad Dermatol. 2022; 86 (1): 68\u201376.",
                        "@id": "45",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0045",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85111342543",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "86",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "68",
                                    "@last": "76"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Enos",
                                        "ce:indexed-name": "Enos C.W."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "V.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Ramos",
                                        "ce:indexed-name": "Ramos V.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.R.",
                                        "@_fa": "true",
                                        "ce:surname": "McLean",
                                        "ce:indexed-name": "McLean R.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Am Acad Dermatol"
                        },
                        "ce:source-text": "Enos CW, Ramos VL, McLean RR, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry. J Am Acad Dermatol. 2022; 86 (1): 68\u201376."
                    },
                    {
                        "ref-fulltext": "Augustin M, Reich K, Yamauchi P, et al. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol. 2022; 186 (6): 942\u2013954.",
                        "@id": "46",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0046",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85128567059",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "186",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "942",
                                    "@last": "954"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Augustin",
                                        "ce:indexed-name": "Augustin M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Reich",
                                        "ce:indexed-name": "Reich K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Yamauchi",
                                        "ce:indexed-name": "Yamauchi P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Br J Dermatol"
                        },
                        "ce:source-text": "Augustin M, Reich K, Yamauchi P, et al. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol. 2022; 186 (6): 942\u2013954."
                    },
                    {
                        "ref-fulltext": "Gordon KB, Colombel JF, Hardin DS. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016; 375 (21): 2102.",
                        "@id": "47",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0047",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85001976260",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "375",
                                    "@issue": "21"
                                },
                                "pagerange": {"@first": "2102"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "K.B.",
                                    "@_fa": "true",
                                    "ce:surname": "Gordon",
                                    "ce:indexed-name": "Gordon K.B."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.F.",
                                    "@_fa": "true",
                                    "ce:surname": "Colombel",
                                    "ce:indexed-name": "Colombel J.F."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "D.S.",
                                    "@_fa": "true",
                                    "ce:surname": "Hardin",
                                    "ce:indexed-name": "Hardin D.S."
                                }
                            ]},
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Gordon KB, Colombel JF, Hardin DS. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016; 375 (21): 2102."
                    },
                    {
                        "ref-fulltext": "Gisondi P, Rovaris M, Piaserico S, et al. Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. Br J Dermatol. 2019; 182 (1): 175\u2013179.",
                        "@id": "48",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0048",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85066843806",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "182",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "175",
                                    "@last": "179"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Gisondi",
                                        "ce:indexed-name": "Gisondi P."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Rovaris",
                                        "ce:indexed-name": "Rovaris M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Piaserico",
                                        "ce:indexed-name": "Piaserico S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Br J Dermatol"
                        },
                        "ce:source-text": "Gisondi P, Rovaris M, Piaserico S, et al. Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. Br J Dermatol. 2019; 182 (1): 175\u2013179."
                    },
                    {
                        "ref-fulltext": "Aichelburg MC, Tanew A. Secukinumab without the initial loading dose in the treatment of plaque-type psoriasis\u2013a simplified dosing regimen at the expense of efficacy? Br J Dermatol. 2020; 182 (1): 18\u201319.",
                        "@id": "49",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Secukinumab without the initial loading dose in the treatment of plaque-type psoriasis\u2013a simplified dosing regimen at the expense of efficacy?"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0049",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85070802069",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "182",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "18",
                                    "@last": "19"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "M.C.",
                                    "@_fa": "true",
                                    "ce:surname": "Aichelburg",
                                    "ce:indexed-name": "Aichelburg M.C."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Tanew",
                                    "ce:indexed-name": "Tanew A."
                                }
                            ]},
                            "ref-sourcetitle": "Br J Dermatol"
                        },
                        "ce:source-text": "Aichelburg MC, Tanew A. Secukinumab without the initial loading dose in the treatment of plaque-type psoriasis\u2013a simplified dosing regimen at the expense of efficacy? Br J Dermatol. 2020; 182 (1): 18\u201319."
                    },
                    {
                        "ref-fulltext": "Bayaraa B, Imafuku S. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka university psoriasis registry. J Dermatol. 2019; 46 (5): 389\u2013398.",
                        "@id": "50",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka university psoriasis registry"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0050",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85062953129",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "46",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "389",
                                    "@last": "398"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "B.",
                                    "@_fa": "true",
                                    "ce:surname": "Bayaraa",
                                    "ce:indexed-name": "Bayaraa B."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "S.",
                                    "@_fa": "true",
                                    "ce:surname": "Imafuku",
                                    "ce:indexed-name": "Imafuku S."
                                }
                            ]},
                            "ref-sourcetitle": "J Dermatol"
                        },
                        "ce:source-text": "Bayaraa B, Imafuku S. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka university psoriasis registry. J Dermatol. 2019; 46 (5): 389\u2013398."
                    },
                    {
                        "ref-fulltext": "Blauvelt A, Reich K, Warren RB, et al. Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. Br J Dermatol. 2017; 177 (3): 879\u2013881.",
                        "@id": "51",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0051",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85029675242",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "177",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "879",
                                    "@last": "881"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Blauvelt",
                                        "ce:indexed-name": "Blauvelt A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Reich",
                                        "ce:indexed-name": "Reich K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Warren",
                                        "ce:indexed-name": "Warren R.B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Br J Dermatol"
                        },
                        "ce:source-text": "Blauvelt A, Reich K, Warren RB, et al. Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. Br J Dermatol. 2017; 177 (3): 879\u2013881."
                    },
                    {
                        "ref-fulltext": "Umezawa Y, Torisu-Itakura H, Morisaki Y, et al. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab. J Eur Acad Dermatol Venereol. 2019; 33 (3): 568\u2013576.",
                        "@id": "52",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0052",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85056405806",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "33",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "568",
                                    "@last": "576"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Umezawa",
                                        "ce:indexed-name": "Umezawa Y."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Torisu-Itakura",
                                        "ce:indexed-name": "Torisu-Itakura H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Morisaki",
                                        "ce:indexed-name": "Morisaki Y."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Eur Acad Dermatol Venereol"
                        },
                        "ce:source-text": "Umezawa Y, Torisu-Itakura H, Morisaki Y, et al. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab. J Eur Acad Dermatol Venereol. 2019; 33 (3): 568\u2013576."
                    },
                    {
                        "ref-fulltext": "Gasslitter I, Kirsten N, Augustin M, et al. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Arch Dermatol Res. 2019; 311 (5): 421\u2013424.",
                        "@id": "53",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0053",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85062953950",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "311",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "421",
                                    "@last": "424"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Gasslitter",
                                        "ce:indexed-name": "Gasslitter I."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Kirsten",
                                        "ce:indexed-name": "Kirsten N."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Augustin",
                                        "ce:indexed-name": "Augustin M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Arch Dermatol Res"
                        },
                        "ce:source-text": "Gasslitter I, Kirsten N, Augustin M, et al. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Arch Dermatol Res. 2019; 311 (5): 421\u2013424."
                    },
                    {
                        "ref-fulltext": "Georgakopoulos JR, Phung M, Ighani A, et al. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: a multicenter retrospective study of interleukin 17A antagonist therapies. J Am Acad Dermatol. 2018; 79 (1): 155\u2013157.",
                        "@id": "54",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: a multicenter retrospective study of interleukin 17A antagonist therapies"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0054",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85048412789",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "79",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "155",
                                    "@last": "157"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Georgakopoulos",
                                        "ce:indexed-name": "Georgakopoulos J.R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Phung",
                                        "ce:indexed-name": "Phung M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Ighani",
                                        "ce:indexed-name": "Ighani A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Am Acad Dermatol"
                        },
                        "ce:source-text": "Georgakopoulos JR, Phung M, Ighani A, et al. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: a multicenter retrospective study of interleukin 17A antagonist therapies. J Am Acad Dermatol. 2018; 79 (1): 155\u2013157."
                    },
                    {
                        "ref-fulltext": "Bokor-Billmann T, SchÃ¤kel K. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis. J Dermatolog Treat. 2019; 30 (3): 216\u2013220.",
                        "@id": "55",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0055",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85053405113",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "30",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "216",
                                    "@last": "220"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "T.",
                                    "@_fa": "true",
                                    "ce:surname": "Bokor-Billmann",
                                    "ce:indexed-name": "Bokor-Billmann T."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "K.",
                                    "@_fa": "true",
                                    "ce:surname": "SchÃ¤kel",
                                    "ce:indexed-name": "Schakel K."
                                }
                            ]},
                            "ref-sourcetitle": "J Dermatolog Treat"
                        },
                        "ce:source-text": "Bokor-Billmann T, SchÃ¤kel K. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis. J Dermatolog Treat. 2019; 30 (3): 216\u2013220."
                    },
                    {
                        "ref-fulltext": "Caldarola G, Mariani M, Pirro F, et al. Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice. Expert Opin Biol Ther. 2021; 21 (2): 279\u2013286.",
                        "@id": "56",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0056",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85099913607",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "21",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "279",
                                    "@last": "286"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Caldarola",
                                        "ce:indexed-name": "Caldarola G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Mariani",
                                        "ce:indexed-name": "Mariani M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Pirro",
                                        "ce:indexed-name": "Pirro F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Expert Opin Biol Ther"
                        },
                        "ce:source-text": "Caldarola G, Mariani M, Pirro F, et al. Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice. Expert Opin Biol Ther. 2021; 21 (2): 279\u2013286."
                    },
                    {
                        "ref-fulltext": "Kromer C, Wilsmann-Theis D, Gerdes S, et al. Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker\u2013a retrospective multicenter study. J Dermatolog Treat. 2021; 32 (8): 878\u2013882.",
                        "@id": "57",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker\u2013a retrospective multicenter study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0057",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85081569689",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "32",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "878",
                                    "@last": "882"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Kromer",
                                        "ce:indexed-name": "Kromer C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Wilsmann-Theis",
                                        "ce:indexed-name": "Wilsmann-Theis D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Gerdes",
                                        "ce:indexed-name": "Gerdes S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Dermatolog Treat"
                        },
                        "ce:source-text": "Kromer C, Wilsmann-Theis D, Gerdes S, et al. Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker\u2013a retrospective multicenter study. J Dermatolog Treat. 2021; 32 (8): 878\u2013882."
                    },
                    {
                        "ref-fulltext": "Menter A, Armstrong A, Van Voorhees A, et al. Brodalumab to the rescue: efficacy and safety of brodalumab in patients with psoriasis and prior exposure or inadequate response to biologics. Dermatol Ther (Heidelb). 2020; 10 (4): 615\u2013621.",
                        "@id": "58",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Brodalumab to the rescue: efficacy and safety of brodalumab in patients with psoriasis and prior exposure or inadequate response to biologics"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0058",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85086375325",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "10",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "615",
                                    "@last": "621"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Menter",
                                        "ce:indexed-name": "Menter A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Armstrong",
                                        "ce:indexed-name": "Armstrong A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Van Voorhees",
                                        "ce:indexed-name": "Van Voorhees A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Dermatol Ther (Heidelb)"
                        },
                        "ce:source-text": "Menter A, Armstrong A, Van Voorhees A, et al. Brodalumab to the rescue: efficacy and safety of brodalumab in patients with psoriasis and prior exposure or inadequate response to biologics. Dermatol Ther (Heidelb). 2020; 10 (4): 615\u2013621."
                    },
                    {
                        "ref-fulltext": "Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018; 178 (3): 674\u2013681.",
                        "@id": "59",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0059",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85042386927",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "178",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "674",
                                    "@last": "681"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Papp",
                                        "ce:indexed-name": "Papp K.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Leonardi",
                                        "ce:indexed-name": "Leonardi C.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Blauvelt",
                                        "ce:indexed-name": "Blauvelt A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Br J Dermatol"
                        },
                        "ce:source-text": "Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018; 178 (3): 674\u2013681."
                    },
                    {
                        "ref-fulltext": "Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis\u2013results of two phase 3 trials. N Engl J Med. 2014; 371 (4): 326\u2013338.",
                        "@id": "60",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Secukinumab in plaque psoriasis\u2013results of two phase 3 trials"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0060",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84904545875",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "371",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "326",
                                    "@last": "338"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.G.",
                                        "@_fa": "true",
                                        "ce:surname": "Langley",
                                        "ce:indexed-name": "Langley R.G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Elewski",
                                        "ce:indexed-name": "Elewski B.E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Lebwohl",
                                        "ce:indexed-name": "Lebwohl M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis\u2013results of two phase 3 trials. N Engl J Med. 2014; 371 (4): 326\u2013338."
                    },
                    {
                        "ref-fulltext": "Fujita H, Ohtsuki M, Morita A, et al. Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: real-world evidence in Japan. J Dermatol. 2021; 48 (2): 175\u2013183.",
                        "@id": "61",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: real-world evidence in Japan"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0061",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85093649374",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "48",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "175",
                                    "@last": "183"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Fujita",
                                        "ce:indexed-name": "Fujita H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Ohtsuki",
                                        "ce:indexed-name": "Ohtsuki M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Morita",
                                        "ce:indexed-name": "Morita A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Dermatol"
                        },
                        "ce:source-text": "Fujita H, Ohtsuki M, Morita A, et al. Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: real-world evidence in Japan. J Dermatol. 2021; 48 (2): 175\u2013183."
                    },
                    {
                        "ref-fulltext": "Huang H, Cai ML, Hong XJ, et al. Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients. Eur J Dermatol. 2020; 30 (5): 554\u2013560.",
                        "@id": "62",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0062",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85096202609",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "30",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "554",
                                    "@last": "560"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Huang",
                                        "ce:indexed-name": "Huang H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Cai",
                                        "ce:indexed-name": "Cai M.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "X.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Hong",
                                        "ce:indexed-name": "Hong X.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Eur J Dermatol"
                        },
                        "ce:source-text": "Huang H, Cai ML, Hong XJ, et al. Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients. Eur J Dermatol. 2020; 30 (5): 554\u2013560."
                    },
                    {
                        "ref-fulltext": "Augustin M, Jullien D, Martin A, et al. Real-world evidence of secukinumab in psoriasis treatment\u2013a meta-analysis of 43 studies. J Eur Acad Dermatol Venereol. 2020; 34 (6): 1174\u20131185.",
                        "@id": "63",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Real-world evidence of secukinumab in psoriasis treatment\u2013a meta-analysis of 43 studies"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0063",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85079705050",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "34",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "1174",
                                    "@last": "1185"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Augustin",
                                        "ce:indexed-name": "Augustin M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Jullien",
                                        "ce:indexed-name": "Jullien D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Martin",
                                        "ce:indexed-name": "Martin A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Eur Acad Dermatol Venereol"
                        },
                        "ce:source-text": "Augustin M, Jullien D, Martin A, et al. Real-world evidence of secukinumab in psoriasis treatment\u2013a meta-analysis of 43 studies. J Eur Acad Dermatol Venereol. 2020; 34 (6): 1174\u20131185."
                    },
                    {
                        "ref-fulltext": "Megna M, Di Costanzo L, Argenziano G, et al. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin Biol Ther. 2019; 19 (8): 855\u2013861.",
                        "@id": "64",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0064",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85066807393",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "19",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "855",
                                    "@last": "861"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Megna",
                                        "ce:indexed-name": "Megna M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Di Costanzo",
                                        "ce:indexed-name": "Di Costanzo L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Argenziano",
                                        "ce:indexed-name": "Argenziano G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Expert Opin Biol Ther"
                        },
                        "ce:source-text": "Megna M, Di Costanzo L, Argenziano G, et al. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin Biol Ther. 2019; 19 (8): 855\u2013861."
                    },
                    {
                        "ref-fulltext": "Chen YC, Huang YT, Yang CC, et al. Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: an analysis of 75 patients in Taiwan. PLoS One. 2020; 15 (12): e0244620.",
                        "@id": "65",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: an analysis of 75 patients in Taiwan"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0065",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "e0244620",
                                    "@idtype": "ARTNUM"
                                },
                                {
                                    "$": "85098965025",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {
                                "@volume": "15",
                                "@issue": "12"
                            }},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Chen",
                                        "ce:indexed-name": "Chen Y.C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Huang",
                                        "ce:indexed-name": "Huang Y.T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Yang",
                                        "ce:indexed-name": "Yang C.C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "PLoS One"
                        },
                        "ce:source-text": "Chen YC, Huang YT, Yang CC, et al. Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: an analysis of 75 patients in Taiwan. PLoS One. 2020; 15 (12): e0244620."
                    },
                    {
                        "ref-fulltext": "Gulliver W, Penney M, Power R, et al. Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events. J Dermatolog Treat. 2022; 33 (1): 354\u2013360.",
                        "@id": "66",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0066",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85083831037",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "33",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "354",
                                    "@last": "360"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "W.",
                                        "@_fa": "true",
                                        "ce:surname": "Gulliver",
                                        "ce:indexed-name": "Gulliver W."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Penney",
                                        "ce:indexed-name": "Penney M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Power",
                                        "ce:indexed-name": "Power R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Dermatolog Treat"
                        },
                        "ce:source-text": "Gulliver W, Penney M, Power R, et al. Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events. J Dermatolog Treat. 2022; 33 (1): 354\u2013360."
                    },
                    {
                        "ref-fulltext": "Deza G, Notario J, Lopez-Ferrer A, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol. 2019; 33 (3): 553\u2013559.",
                        "@id": "67",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0067",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85056416493",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "33",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "553",
                                    "@last": "559"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Deza",
                                        "ce:indexed-name": "Deza G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Notario",
                                        "ce:indexed-name": "Notario J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Lopez-Ferrer",
                                        "ce:indexed-name": "Lopez-Ferrer A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Eur Acad Dermatol Venereol"
                        },
                        "ce:source-text": "Deza G, Notario J, Lopez-Ferrer A, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol. 2019; 33 (3): 553\u2013559."
                    },
                    {
                        "ref-fulltext": "Zhang C, Yan K, Diao Q, et al. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2022;87(1): 95\u2013102.",
                        "@id": "68",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0068",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85125483446",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"pagerange": {
                                "@first": "95",
                                "@last": "102"
                            }},
                            "ref-text": "87(1",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhang",
                                        "ce:indexed-name": "Zhang C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Yan",
                                        "ce:indexed-name": "Yan K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Q.",
                                        "@_fa": "true",
                                        "ce:surname": "Diao",
                                        "ce:indexed-name": "Diao Q."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Am Acad Dermatol"
                        },
                        "ce:source-text": "Zhang C, Yan K, Diao Q, et al. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2022;87(1): 95\u2013102."
                    },
                    {
                        "ref-fulltext": "Girolomoni G, Griffiths CE, Krueger J, et al. Early intervention in psoriasis and immune-mediated inflammatory diseases: a hypothesis paper. J Dermatolog Treat. 2015; 26 (2): 103\u2013112.",
                        "@id": "69",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Early intervention in psoriasis and immune-mediated inflammatory diseases: a hypothesis paper"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0069",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84930812067",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "26",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "103",
                                    "@last": "112"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Girolomoni",
                                        "ce:indexed-name": "Girolomoni G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Griffiths",
                                        "ce:indexed-name": "Griffiths C.E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Krueger",
                                        "ce:indexed-name": "Krueger J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Dermatolog Treat"
                        },
                        "ce:source-text": "Girolomoni G, Griffiths CE, Krueger J, et al. Early intervention in psoriasis and immune-mediated inflammatory diseases: a hypothesis paper. J Dermatolog Treat. 2015; 26 (2): 103\u2013112."
                    },
                    {
                        "ref-fulltext": "Acosta Felquer ML, LoGiudice L, Galimberti ML, et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2022; 81 (1): 74\u201379.",
                        "@id": "70",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0070",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85110856000",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "81",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "74",
                                    "@last": "79"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Acosta Felquer",
                                        "ce:indexed-name": "Acosta Felquer M.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "LoGiudice",
                                        "ce:indexed-name": "LoGiudice L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Galimberti",
                                        "ce:indexed-name": "Galimberti M.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Rheum Dis"
                        },
                        "ce:source-text": "Acosta Felquer ML, LoGiudice L, Galimberti ML, et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2022; 81 (1): 74\u201379."
                    },
                    {
                        "ref-fulltext": "Veronesi G, Guglielmo A, Gardini A, et al. Biological therapy in patients with psoriasis: What we know about the effects on renal function. Dermatol Ther. 2022; 35 (1): e15202.",
                        "@id": "71",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Biological therapy in patients with psoriasis: What we know about the effects on renal function"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0071",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85119847495",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "35",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "e15202"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Veronesi",
                                        "ce:indexed-name": "Veronesi G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Guglielmo",
                                        "ce:indexed-name": "Guglielmo A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Gardini",
                                        "ce:indexed-name": "Gardini A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Dermatol Ther"
                        },
                        "ce:source-text": "Veronesi G, Guglielmo A, Gardini A, et al. Biological therapy in patients with psoriasis: What we know about the effects on renal function. Dermatol Ther. 2022; 35 (1): e15202."
                    },
                    {
                        "ref-fulltext": "von Stebut E, Reich K, ThaÃ§i D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol. 2019; 139 (5): 1054\u20131062.",
                        "@id": "72",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0072",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85061429923",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "139",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "1054",
                                    "@last": "1062"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "von Stebut",
                                        "ce:indexed-name": "von Stebut E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Reich",
                                        "ce:indexed-name": "Reich K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "ThaÃ§i",
                                        "ce:indexed-name": "Thaci D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Invest Dermatol"
                        },
                        "ce:source-text": "von Stebut E, Reich K, ThaÃ§i D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol. 2019; 139 (5): 1054\u20131062."
                    },
                    {
                        "ref-fulltext": "Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019; 115 (4): 721\u2013728.",
                        "@id": "73",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0073",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85063375724",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "115",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "721",
                                    "@last": "728"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Elnabawi",
                                        "ce:indexed-name": "Elnabawi Y.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Dey",
                                        "ce:indexed-name": "Dey A.K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Goyal",
                                        "ce:indexed-name": "Goyal A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cardiovasc Res"
                        },
                        "ce:source-text": "Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019; 115 (4): 721\u2013728."
                    },
                    {
                        "ref-fulltext": "Damiani G, Odorici G, Pacifico A, et al. Secukinumab loss of efficacy is perfectly counteracted by the introduction of combination therapy (rescue therapy): data from a multicenter Real-Life study in a cohort of Italian psoriatic patients that avoided secukinumab switching. Pharmaceuticals (Basel). 2022; 15 (1): 95.",
                        "@id": "74",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2022"},
                            "ref-title": {"ref-titletext": "Secukinumab loss of efficacy is perfectly counteracted by the introduction of combination therapy (rescue therapy): data from a multicenter Real-Life study in a cohort of Italian psoriatic patients that avoided secukinumab switching"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0074",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85123106503",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "15",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "95"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Damiani",
                                        "ce:indexed-name": "Damiani G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Odorici",
                                        "ce:indexed-name": "Odorici G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Pacifico",
                                        "ce:indexed-name": "Pacifico A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Pharmaceuticals (Basel)"
                        },
                        "ce:source-text": "Damiani G, Odorici G, Pacifico A, et al. Secukinumab loss of efficacy is perfectly counteracted by the introduction of combination therapy (rescue therapy): data from a multicenter Real-Life study in a cohort of Italian psoriatic patients that avoided secukinumab switching. Pharmaceuticals (Basel). 2022; 15 (1): 95."
                    }
                ]
            }}
        }
    },
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60002620",
        "affilname": "Faculty of Medicine, Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
        "affiliation-country": "Thailand"
    },
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85132820752",
        "dc:description": "Background: Off-label uses of biologics in the treatment of psoriasis are usually implemented in limited-resource settings and studies regarding their response profiles are limited. Method: This was a retrospective study performed in moderate-to-severe plaque-type psoriasis patients who had been treated with either secukinumab, ixekizumab or brodalumab at a university hospital in Thailand between 1 January 2017 and 1 April 2021. Results: A total of 142 patients were included in the data analysis consisting of three groups of 48 patients, 86 patients, and 8 patients treated by secukinumab, ixekizumab, and brodalumab, respectively. Patients were then classified into five groups according to the dosing pattern they received; on-label, off-label with induction, off-label with specific pattern, off-label with irregular dosing interval <8 weeks and >8 weeks. Considering both secukinumab and ixekizumab, the adjusted hazard ratios (95%CI) for complete skin clearance of the four off-label regimens were 2.2(0.9\u20135.2), 1.9 (0.9\u20133.9), 1.0 (0.4\u20132.2), and 1.6 (0.7\u20133.6), compared to on-label regimen, respectively. In each biologic drug, almost all off-label dosing regimens demonstrated higher adjusted hazard ratios compared to on-label regimen. Conclusion: Off-label, patient-oriented regimens could be a promising choice of IL-17 inhibitors for administration in special settings. Off-label regimens are not inferior in terms of skin clearance to an on-label regimen in the efficacy of psoriasis treatment of secukinumab and ixekizumab but do cause more flares. The decision to use off-label regimens must account for the benefits and associated risks.",
        "pubmed-id": "35695280",
        "prism:coverDate": "2022-01-01",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85132820752",
        "dc:creator": {"author": [{
            "ce:given-name": "Pim",
            "preferred-name": {
                "ce:given-name": "Pim",
                "ce:initials": "P.",
                "ce:surname": "Sermsaksasithorn",
                "ce:indexed-name": "Sermsaksasithorn P."
            },
            "@seq": "1",
            "ce:initials": "P.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002620",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
            },
            "ce:surname": "Sermsaksasithorn",
            "@auid": "57763746000",
            "author-url": "https://api.elsevier.com/content/author/author_id/57763746000",
            "ce:indexed-name": "Sermsaksasithorn P."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85132820752"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85132820752&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85132820752&origin=inward"
            }
        ],
        "source-id": "24862",
        "citedby-count": "0",
        "prism:volume": "33",
        "subtype": "ar",
        "dc:title": "On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study",
        "openaccess": "0",
        "prism:issn": "14711753 09546634",
        "publishercopyright": "Â© 2022 Taylor & Francis Group, LLC.",
        "prism:issueIdentifier": "7",
        "subtypeDescription": "Article",
        "prism:publicationName": "Journal of Dermatological Treatment",
        "prism:pageRange": "2963-2974",
        "prism:endingPage": "2974",
        "openaccessFlag": "false",
        "prism:doi": "10.1080/09546634.2022.2089328",
        "prism:startingPage": "2963",
        "dc:identifier": "SCOPUS_ID:85132820752",
        "dc:publisher": "Taylor and Francis Ltd."
    },
    "idxterms": {"mainterm": [
        {
            "$": "Antibodies, Monoclonal",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Biological Products",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Humans",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Interleukin Inhibitors",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Interleukin-17",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Off-Label Use",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Psoriasis",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Retrospective Studies",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Severity of Illness Index",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Thailand",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Treatment Outcome",
            "@weight": "b",
            "@candidate": "n"
        }
    ]},
    "language": {"@xml:lang": "eng"},
    "authkeywords": {"author-keyword": [
        {
            "@_fa": "true",
            "$": "biologics"
        },
        {
            "@_fa": "true",
            "$": "brodalumab"
        },
        {
            "@_fa": "true",
            "$": "interleukin-17 inhibitors"
        },
        {
            "@_fa": "true",
            "$": "ixekizumab"
        },
        {
            "@_fa": "true",
            "$": "Psoriasis"
        },
        {
            "@_fa": "true",
            "$": "secukinumab"
        }
    ]},
    "subject-areas": {"subject-area": [{
        "@_fa": "true",
        "$": "Dermatology",
        "@code": "2708",
        "@abbrev": "MEDI"
    }]},
    "authors": {"author": [
        {
            "ce:given-name": "Pim",
            "preferred-name": {
                "ce:given-name": "Pim",
                "ce:initials": "P.",
                "ce:surname": "Sermsaksasithorn",
                "ce:indexed-name": "Sermsaksasithorn P."
            },
            "@seq": "1",
            "ce:initials": "P.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002620",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
            },
            "ce:surname": "Sermsaksasithorn",
            "@auid": "57763746000",
            "author-url": "https://api.elsevier.com/content/author/author_id/57763746000",
            "ce:indexed-name": "Sermsaksasithorn P."
        },
        {
            "ce:given-name": "Chanidapa",
            "preferred-name": {
                "ce:given-name": "Chanidapa",
                "ce:initials": "C.",
                "ce:surname": "Wongtada",
                "ce:indexed-name": "Wongtada C."
            },
            "@seq": "2",
            "ce:initials": "C.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002620",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
            },
            "ce:surname": "Wongtada",
            "@auid": "57226428403",
            "author-url": "https://api.elsevier.com/content/author/author_id/57226428403",
            "ce:indexed-name": "Wongtada C."
        },
        {
            "ce:given-name": "Varin",
            "preferred-name": {
                "ce:given-name": "Varin",
                "ce:initials": "V.",
                "ce:surname": "Chaaim",
                "ce:indexed-name": "Chaaim V."
            },
            "@seq": "3",
            "ce:initials": "V.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002620",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
            },
            "ce:surname": "Chaaim",
            "@auid": "57764420400",
            "author-url": "https://api.elsevier.com/content/author/author_id/57764420400",
            "ce:indexed-name": "Chaaim V."
        },
        {
            "ce:given-name": "Yuda",
            "preferred-name": {
                "ce:given-name": "Yuda",
                "ce:initials": "Y.",
                "ce:surname": "Chongpison",
                "ce:indexed-name": "Chongpison Y."
            },
            "@seq": "4",
            "ce:initials": "Y.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002620",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
            },
            "ce:surname": "Chongpison",
            "@auid": "6504499118",
            "author-url": "https://api.elsevier.com/content/author/author_id/6504499118",
            "ce:indexed-name": "Chongpison Y."
        },
        {
            "ce:given-name": "Pravit",
            "preferred-name": {
                "ce:given-name": "Pravit",
                "ce:initials": "P.",
                "ce:surname": "Asawanonda",
                "ce:indexed-name": "Asawanonda P."
            },
            "@seq": "5",
            "ce:initials": "P.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002620",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
            },
            "ce:surname": "Asawanonda",
            "@auid": "6603000286",
            "author-url": "https://api.elsevier.com/content/author/author_id/6603000286",
            "ce:indexed-name": "Asawanonda P."
        }
    ]}
}}